Immuron (NASDAQ:IMRN) Releases Quarterly Earnings Results

Posted by Casey Walker on May 1st, 2026

Immuron (NASDAQ:IMRN – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, FiscalAI reports. The firm had revenue of $1.40 million for the quarter.

Immuron Price Performance

Shares of NASDAQ IMRN traded up $0.03 during trading hours on Friday, hitting $0.85. 9,441 shares of the stock were exchanged, compared to its average volume of 38,454. The company’s 50 day moving average is $0.81 and its 200 day moving average is $1.13. Immuron has a one year low of $0.68 and a one year high of $2.39.

Institutional Trading of Immuron

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC acquired a new position in shares of Immuron (NASDAQ:IMRN – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.29% of Immuron at the end of the most recent quarter. Institutional investors and hedge funds own 0.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Immuron in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Read Our Latest Analysis on IMRN

Immuron Company Profile

(Get Free Report)

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.